Skip to content

Ultrasound-guided Pulsed Radiofrequency for Plantar Fasciitis

Ultrasound-guided Pulsed Radiofrequency Stimulation of the Tibial Nerve for Plantar Fasciitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02242513
Enrollment
36
Registered
2014-09-17
Start date
2014-04-30
Completion date
2016-07-31
Last updated
2016-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar Fasciitis

Keywords

Pulsed mode radiofrequency, Plantar Fasciitis, Ultrasound-guided

Brief summary

Although there are many conservative method for plantar fasciitis, patients might spend 2 years to achieve resolution. Recent study have shown that pulsed radiofrequency (PRF) lesioning of peripheral nerve can alleviate kinds of pain condition. However there are no studies of PRF lesioning of the tibial nerve in patients with plantar fascilitis by using ultrasound-guided (UG) techniques.

Detailed description

Patients with unilateral plantar Fasciitis will be enrolled and randomized into intervention and control group. One dose of sono-guided PRF is applied in the intervention group and xylocaine in control group. Outcome measurements included visual analog scale (VAS)、foot health status questionnaire and the thickness of plantar fascile measured by musculoskeletal ultrasonography at different follow-up frame (4th week, 2nd month, 3rd month after treatment).

Interventions

Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.

Sponsors

Yung-Tsan Wu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Heel pain more than 3 months * Age more than 20 year-old * The increased thickness of plantar fascile (\>4mm) measured by sonography * Must be conscious * Not receive steroid or other injection in plantar fascile in past 6 months

Exclusion criteria

* Cancer of any site * Coagulopathy * Pregnancy * Inflammation status

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline of pain on 4th, 8th and 12th weeks after treatment.Baseline , 4th, 8th and 12th weeks after treatment.Using the Visual analog scale (VAS) and subscore of foot health status questionnaire to measure the pain scale before treatment and multiple time frame after treatment.

Secondary

MeasureTime frameDescription
Change from baseline of functional improvement on 4th, 8th and 12th after treatment.Baseline , 4th, 8th and 12th weeks after treatment.Using the functional subscore of foot health status questionnaire to measure the functional socre before treatment and multiple time frame after treatment.
Change from baseline of thickness of plantar fascile on 4th, 8th and 12th weeks after treatment.Baseline , 4th, 8th and 12th weeks after treatment.Using the musculoskeletal ultrasonography to measure the thickness before treatment and multiple time frame after treatment.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026